SCHEMBL310266

SCHEMBL310266

NC(=O)c1cnccc1N

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.62
SIRT3 Q9NTG7 2/20 0.62
KDM4E B2RXH2 3/20 0.53
ALDH1A1 P00352 2/20 0.53
MEN1 O00255 1/20 0.53
KDM6B O15054 1/20 0.53
KDM4A O75164 1/20 0.53
MAPT P10636 1/20 0.53
THRB P10828 1/20 0.53
KMT2A Q03164 1/20 0.53
KDM4D Q6B0I6 1/20 0.53
KDM4C Q9H3R0 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
GAA P10253 2/20 0.47
GLA P06280 1/20 0.47
HTT P42858 1/20 0.46
F7 P08709 1/20 0.45
F3 P13726 1/20 0.45
SARM1 Q6SZW1 1/20 0.45
SIRT2 Q8IXJ6 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL11483542 0.98 TDP1 (0.60) TDP1SIRT3KDM4EALDH1A1MEN1
SCHEMBL11098872 0.84 KDM4C (0.61) TDP1SIRT3KDM4EALDH1A1MEN1
SCHEMBL244632 0.83 KDM4C (0.70) TDP1SIRT3KDM4EALDH1A1MEN1
SCHEMBL2139056 0.83 KDM4E (0.70) TDP1SIRT3KDM4EALDH1A1MEN1
SCHEMBL220890 0.83 KDM4C (0.70) TDP1SIRT3KDM4EALDH1A1MEN1
SCHEMBL30785801 0.83 KDM4C (0.70) TDP1SIRT3KDM4EALDH1A1MEN1
SCHEMBL1687197 0.82 TDP1 (0.67) TDP1SIRT3KDM4EALDH1A1MEN1
SCHEMBL1330970 0.82 TDP1 (0.67) TDP1SIRT3KDM4EALDH1A1MEN1
Ammonia Solution, Strong SCHEMBL11786496 0.81 KDM4C (0.68) TDP1SIRT3KDM4EALDH1A1MEN1
Ammonia Solution, Strong SCHEMBL11786508 0.81 KDM4C (0.68) TDP1SIRT3KDM4EALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 308 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024148139-A2 METABOLITE-BASED PARTICLES AND COMPOSITIONS THEREOF FOR PREVENTING AND TREATING NEUROLOGICAL DISEASES AND DISORDERS ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2024-07-11 WO claimed
CN-103609593-B Agricultural composition with function of sugar increase and coloring of fruit Hebei Academy of Forestry Science 2014-12-03 CN claimed
CN-103609593-A Agricultural composition with function of sugar increase and coloring of fruit Hebei Academy of Forestry Science 2014-03-05 CN claimed
EP-2635556-A2 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS Portola Pharmaceuticals, Inc. (US) 2013-09-11 EP claimed
CN-102633715-A Inhibitor of mitogen protein kinase p38 and preparation method of inhibitor WUXI ALLNATURE NUTRITION HEALTH CARE PRODUCT TECHNOLOGY CO LTD 2012-08-15 CN claimed
WO-2012061418-A2 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-05-10 WO claimed
CN-101765425-A Use of benzamide derivatives for the treatment of CNS disorders HOFFMANN LA ROCHE 2010-06-30 CN claimed
EP-4127157-B1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS ENCODIA INC (US) 2026-02-11 EP disclosed
WO-2025143877-A1 DERIVATIVE COMPOUND COMPRISING AMINO NICOTINAMIDE STRUCTURE AND ANTIFUNGAL PHARMACEUTICAL COMPOSITION COMPRISING SAME (주)앰틱스바이오 2025-07-03 WO disclosed
WO-2025143305-A1 DERIVATIVE COMPOUND COMPRISING AMINO NICOTINAMIDE STRUCTURE AND ANTIFUNGAL PHARMACEUTICAL COMPOSITION CONTAINING SAME (주)앰틱스바이오 2025-07-03 WO disclosed
CN-111699176-B Quinazolinones as PARP14 inhibitors 里邦医疗公司 2025-02-14 CN disclosed
US-11993585-B2 Poly-ADP ribose polymerase (PARP) inhibitors MITOBRIDGE, INC. (US) 2024-05-28 US disclosed
US-11958837-B2 Quinazolinones as PARP14 inhibitors RIBON THERAPEUTICS, INC. (US) 2024-04-16 US disclosed
US-4885291-A 1-carba(dethia)-3-cephem derivatives ELI LILLY AND COMPANY (US) 1989-12-05 US disclosed
EP-0324562-A1 1-Carba(dethia)-3-cephem derivatives ELI LILLY AND COMPANY (US) 1989-07-19 EP disclosed
US-4791106-A 1-Carbacephalosporin antibiotics ELI LILLY AND COMPANY (US) 1988-12-13 US disclosed
EP-0232623-A1 1-Carbacephalosporin antibiotics ELI LILLY AND COMPANY (US) 1987-08-19 EP disclosed
US-4129643-A Method for rapid screening of teratogenic agents CLAYTON RUTH M 1978-12-12 US disclosed
US-4067741-A Hardening photographic layers containing silver halide with a 1-sulphonyl-4-amino-pyridinium salt AGFA-GEVAERT, A.G. (DT) 1978-01-10 US disclosed
US-3970663-A Certain amino-nicotinamide derivatives SCIENCE UNION ET CIE, SOCIETE FRANCAISE DE RECHERCHE MEDICAL (FR) 1976-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11993585-B2 Poly-ADP ribose polymerase (PARP) inhibitors PARP1, PARP2, PARP11 TDP1 40/4885SIRT3 147/4885KDM4E 2486/4885
US-11958837-B2 Quinazolinones as PARP14 inhibitors PARP14, PARP15, PARP11 TDP1 120/4885SIRT3 33/4885KDM4E 383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.